Exploiting the hydrophobic channel of the NNIBP: Discovery of novel diarylpyrimidines as HIV-1 NNRTIs against wild-type and K103N mutant viruses

被引:5
|
作者
Fu, Zhipeng [1 ]
Zhang, Tao [1 ]
Zhou, Zhongxia [1 ]
Kang, Dongwei [1 ]
Sun, Lin [1 ]
Gao, Shenghua [1 ]
Cherukupalli, Srinivasulu [1 ]
De Clercq, Erik [2 ]
Pannecouque, Christophe [2 ]
Liu, Xinyong [1 ,3 ]
Zhan, Peng [1 ,3 ]
机构
[1] Shandong Univ, Cheeloo Coll Med, Sch Pharmaceut Sci, Dept Med Chem,Key Lab Chem Biol,Minist Educ, 44 West Culture Rd, Jinan 250012, Shandong, Peoples R China
[2] Katholieke Univ Leuven, Rega Inst Med Res, Lab Virol & Chemotherapy, Herestr 49 Postbus 1043 09-A097, B-3000 Leuven, Belgium
[3] China Belgium Collaborat Res Ctr Innovat Antivira, 44 West Culture Rd, Jinan 250012, Shandong, Peoples R China
基金
中国国家自然科学基金;
关键词
HIV-1; NNRTI; Drug design; Drug resistance; Antiviral drug; REVERSE-TRANSCRIPTASE INHIBITORS; COLORIMETRIC ASSAY; ETRAVIRINE TMC125; DRUG; DERIVATIVES; POTENCY; DESIGN;
D O I
10.1016/j.bmc.2021.116239
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
To further explore the chemical space surrounding the "hydrophobic channel" of the NNRTI binding pocket (NNIBP), a new series of diarylpyrimidines (DAPYs) were designed and synthesized as potent HIV-1 nonnucleoside RT inhibitors (NNRTIs). The target compounds were evaluated for anti-HIV potency in MT-4 cells. Most of the synthesized DAPYs exhibited moderate to excellent activity against the HIV-1 wild-type (WT) strain with EC50 values ranging from 16 nM to 0.722 mu M. Interestingly, few compounds displayed remarkable activity in inhibiting K103N mutant virus with EC50 values ranging from 39 nM to 1.708 mu M. Notably, FS2 (EC50(IIIB) = 16 nM, EC50(K103N) = 39 nM, SI = 294) was identified as the most significant compound, which was considerably more potent than nevirapine, lamivudine, and comparable to zidovudine. Additionally, the HIV-1 RT inhibition assay confirmed their binding target. Preliminary structure-activity relationships (SARs) and molecular modeling studies were also performed, providing significant suggestions for further optimization.
引用
收藏
页数:11
相关论文
共 36 条
  • [21] Towards discovering dual functional inhibitors against both wild type and K103N mutant HIV-1 reverse transcriptases: molecular docking and QSAR studies on 4,1-benzoxazepinone analogues
    Zhenshan Zhang
    Mingyue Zheng
    Li Du
    Jianhua Shen
    Xiaomin Luo
    Weiliang Zhu
    Hualiang Jiang
    Journal of Computer-Aided Molecular Design, 2006, 20 : 281 - 293
  • [22] Cryo-EM structures of wild-type and E138K/M184I mutant HIV-1 RT/DNA complexed with inhibitors doravirine and rilpivirine
    Singh, Abhimanyu K.
    De Wijngaert, Brent
    Bijnens, Marc
    Uyttersprot, Kris
    Nguyen, Hoai
    Martinez, Sergio E.
    Schols, Dominique
    Herdewijn, Piet
    Pannecouque, Christophe
    Arnold, Eddy
    Das, Kalyan
    PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2022, 119 (30)
  • [23] Synthesis of novel diarylpyrimidine analogues of TMC278 and their antiviral activity against HIV-1 wild-type and mutant strains
    Mordant, Celine
    Schmitt, Benoit
    Pasquier, Elisabeth
    Demestre, Christophe
    Queguiner, Laurence
    Masungi, Chantal
    PeeterS, Anik
    Smeulders, Liesbeth
    Bettens, Eva
    Hertogs, Kurt
    Heeres, Jan
    Lewi, Paul
    Guillemont, Jerome
    EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2007, 42 (05) : 567 - 579
  • [24] Follow on-based optimization of the biphenyl-DAPYs as HIV-1 nonnucleoside reverse transcriptase inhibitors against the wild-type and mutant strains
    Sang, Yali
    Han, Sheng
    Han, Shuwen
    Pannecouque, Christophe
    De Clercq, Erik
    Zhuang, Chunlin
    Chen, Fener
    BIOORGANIC CHEMISTRY, 2019, 89
  • [25] Molecular Hybridization-Inspired Optimization of Diarylbenzopyrimidines as HIV-1 Nonnucleoside Reverse Transcriptase Inhibitors with Improved Activity against K103N and E138K Mutants and Pharmacokinetic Profiles
    Han, Sheng
    Sang, Yali
    Wu, Yan
    Tao, Yuan
    Pannecouque, Christophe
    De Clercq, Erik
    Zhuang, Chunlin
    Che, Fen-Er
    ACS INFECTIOUS DISEASES, 2020, 6 (05): : 787 - 801
  • [26] 2,4,5-Trisubstituted thiazole derivatives as HIV-1 NNRTIs effective on both wild-type and mutant HIV-1 reverse transcriptase: Optimization of the substitution of positions 4 and 5
    Xu, Zhongliang
    Guo, Jiamei
    Yang, Ying
    Zhang, Mengdi
    Ba, Mingyu
    Li, Zhenzhong
    Cao, Yingli
    He, Ricai
    Yu, Miao
    Zhou, Hua
    Li, Xiaoxi
    Huang, Xiaoshan
    Guo, Ying
    Guo, Changbin
    EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2016, 123 : 309 - 316
  • [27] Structural basis for the inhibitory efficacy of efavirenz (DMP-266), MSC194 and PNU142721 towards the HIV-1 RT K103N mutant
    Lindberg, J
    Sigurdsson, S
    Löwgren, S
    Andersson, HO
    Sahlberg, C
    Noréen, R
    Fridborg, K
    Zhang, H
    Unge, T
    EUROPEAN JOURNAL OF BIOCHEMISTRY, 2002, 269 (06): : 1670 - 1677
  • [28] Investigating potency of TMC-126 against wild-type and mutant variants of HIV-1 protease: a molecular dynamics and free energy study
    Sk, M. F.
    Haridev, S.
    Roy, R.
    Kar, P.
    SAR AND QSAR IN ENVIRONMENTAL RESEARCH, 2021, 32 (11) : 941 - 962
  • [29] 3D-QSAR models on clinically relevant K103N mutant HIV-1 reverse transcriptase obtained from two strategic considerations
    Juan, Amor A. San
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2008, 18 (03) : 1181 - 1194
  • [30] Novel HIV-1 Non-nucleoside Reverse Transcriptase Inhibitor Agents: Optimization of Diarylanilines with High Potency against Wild-Type and Rilpivirine-Resistant E138K Mutant Virus
    Liu, Na
    Wei, Lei
    Huang, Li
    Yu, Fei
    Zheng, Weifan
    Qin, Bingjie
    Zhu, Dong-Qin
    Morris-Natschke, Susan L.
    Jiang, Shibo
    Chen, Chin-Ho
    Lee, Kuo-Hsiung
    Xie, Lan
    JOURNAL OF MEDICINAL CHEMISTRY, 2016, 59 (08) : 3689 - 3704